Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting

Asthma Clinical Trial

— EHD-Pred PK  

Official title:

Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05012033
• Other study ID #: 21HH6792
• Status: Recruiting
• Start date: April 12, 2023
• Est. completion date: March 26, 2026

Study information

• Verified date: September 2023
• Source: Imperial College London
• Contact: Katharine Lazarus, MBChB MRCP
• Phone: 07555717544
• Email: imperial.steroids[@]nhs.net
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a pilot study to investigate serum prednisolone profiles in:

• Patients on high doses of prednisolone for any inflammatory disorder, both in the acute and chronic setting.

• Patients stepping up from or down to prednisolone therapy in association with a course of high dose methyl-prednisolone or dexamethasone.

The study will comprise 3 groups, including those started on high doses of prednisolone acutely in an inpatient or outpatient setting, participants on chronically high doses, and those receiving a several week course of high dose methylprednisolone or dexamethasone.

The study aims to measure prednisolone levels at a number of time points to investigate serum profile differences in those receiving prednisolone acutely compared with longer term steroid use. Further samples will be taken to characterise additional metabolic changes.

Description:

Prednisolone is an anti-inflammatory drug widely used to reduce inflammation and immune activation in a number of medical conditions, including asthma, allergy, inflammatory and auto-immune conditions. Its therapeutic actions, however, are accompanied by several adverse side effects, which are more frequent following high doses and long term treatments. The aim is therefore to use the lowest effective dose or highest dose for the shortest treatment required.

It has been observed in a select number of patients on replacement prednisolone doses for adrenal insufficiency (AI) that serum prednisolone levels change over time, despite patients remaining on the same dose. It is currently unclear whether serum levels of prednisolone match the doses in patients taking high dose prednisolone, both in the acute and chronic setting, and whether the way in which prednisolone is metabolised is altered after receiving high doses for prolonged periods of time.

The rationale for the use of particular doses for particular conditions is not clear, and has been developed historically in the absence of individual patient data. It is possible that more tailored dosing of prednisolone will result in reduced side effects, and that the minimum possible dose may be weight related.

In addition, genetic and epigenetic factors may also play a role in the efficacy of prednisolone and in the risk of developing side effects, accounting for some of the inter-individual variation in drug response.

Further characterising this may help to create an evidence base to tailor anti-inflammatory doses and weaning regimens of synthetic glucocorticoids that avoid deleterious effects.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: March 26, 2026
• Est. primary completion date: March 26, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Aged 18 - 75 years

• Male or female

• Participants who are otherwise healthy enough to participate, as determined by pre-study medical history

• Participants who are able and willing to give written informed consent to participate in the study

• Group A only: Patients requiring acute (<5 days) high dose (minimum 30mg) oral prednisolone therapy for antiinflammatory purposes in either an inpatient or outpatient setting.

• Group B only: Minimum of 1 month duration of high dose prednisolone (>30mg) if in the chronic use group.

• Group C only: Patients started on high dose methylprednisolone (>3 day course) or prolonged courses of dexamethasone.

Exclusion Criteria:

• Participants with a diagnosis of Type 1 or Type 2 diabetes mellitus.

• Unable to give informed consent.

• Taking supplements or herbal medications that the participant is unwilling or unable to stop prior to and during the study period e.g. St John's Wort (may decrease prednisolone levels), Cat's claw, Echinacea (immunomodulatory properties).

• Currently taking medications that alter CYP3A4 metabolism of glucocorticoids that the participant is unwilling or unable to stop prior to and during the study period e.g. phenytoin, phenobarbital, rifampicin, rifabutin, carbamazepine, primidone, aminogluethimide, itraconazole, ketoconazole, ciclosporin or ritonavir.

• Pregnancy. Females of child-bearing age will be asked to provide a urine sample for a pregnancy test at each visit.

• History of any medical, psychological or other condition, or use of any medications, including over-the-counter products, which, in the opinion of the investigators, would either interfere with the study or compromise the safety of the participant.

Related Conditions & MeSH terms

• Asthma
• COPD Exacerbation Acute
• Eye Diseases
• Graves Ophthalmopathy
• Inflammatory Disease
• Thyroid Eye Disease
• Vasculitis

Intervention

Other:
• No intervention - prednisolone is taken as part if routine clinical care.
Prednisolone given orally prior to taking timed samples for levels

Locations

Country	Name	City	State
United Kingdom	Imperial College Healthcare NHS Trust	London

Sponsors (1)

Lead Sponsor	Collaborator
Imperial College London

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To elucidate differences in prednisolone pharmacokinetics (in patients receiving high dose prednisolone acutely and in the chronic setting).	This will be assessed by determination of Cmax	Pharmacokinetics measurements taken at the first and second visits. This will be of variable duration depending on duration of steroid treatment (5 days up to 2 years)
Primary	To elucidate differences in prednisolone pharmacokinetics (in patients receiving high dose	This will be assessed by determination of Tmax	Pharmacokinetics measurements taken at the first and second visits. This will be of variable duration depending on duration of steroid treatment (5 days up to 2 years)
Primary	To elucidate differences in prednisolone pharmacokinetics (in patients receiving high dose	This will be assessed by determination of prednisolone half life and area under the curve values.	Pharmacokinetics measurements taken at the first and second visits. This will be of variable duration depending on duration of steroid treatment (5 days up to 2 years)
Primary	To elucidate differences in prednisolone pharmacokinetics (in patients receiving high dose	This will be assessed by determination of urinary steroid profiles.	Pharmacokinetics measurements taken at the first and second visits. This will be of variable duration depending on duration of steroid treatment (5 days up to 2 years)
Secondary	To elucidate further differences in metabolic profiles and glucocorticoid axis	Assessed by review of bloods, including full blood count (FBC), renal profile, liver function tests (LFTs), creatine kinase (CK), Adrenocorticotropic hormone (ACTH), cortisol, cortisol binding globulin (CBG) and bicarbonate.	Time points post prednisolone dose at 1st and 2nd visits. This will be of variable duration depending on duration of steroid treatment (5 days up to 2 years)
Secondary	Exploratory Outcomes	Metabolomic and metagenomic changes in plasma and urine to investigate inter-individual variation in prednisolone Immunology profiles - assessed by measurement and assessment of soluble immunological analytes and isolated white cell populations; metabolism	Time points post prednisolone dose at 1st and 2nd visits. This will be of variable duration depending on duration of steroid treatment (5 days up to 2 years)
Secondary	Surrogate markers and risk factors for cardiovascular disease	Anthropometric markers such as blood pressure	On 1st and 2nd visits
Secondary	Surrogate markers and risk factors for cardiovascular disease	Anthropometric markers such as heart rate	On 1st and 2nd visits
Secondary	Surrogate markers and risk factors for cardiovascular disease	Anthropometric markers such as BMI	On 1st and 2nd visits. This will be of variable duration depending on duration of steroid treatment (5 days up to 2 years)
Secondary	Surrogate markers and risk factors for cardiovascular disease	Anthropometric markers such aswaist-hip circumference ratio.	On 1st and 2nd visits. This will be of variable duration depending on duration of steroid treatment (5 days up to 2 years)